1 Study Matches
Phase I Study of Carfilzomib in combination with Cyclophosphamide and Etoposide for Children with Relapsed or Refractory Solid Tumors and Leukemias
A study of the safety of carfilzomib for children with solid tumors and leukemias that returned or did not respond to previous treatment.
Inclusion Criteria:Diagnosis of relapsed or refractory solid tumor.
Age 6 months to less than 30 years at enrollment.
Must be fully recovered from effects of previous treatment.
Life expectancy greater than or equal to 3 months.
Exclusion Criteria:Prior treatment with carfilzomib.
Known allergy to Captisol®.
Children's Health, Cancer